(Q32058584)

6 July 2017

1 reference

title

The role of fluoroquinolones in tuberculosis today (English)

1 reference

6 July 2017

0 references

Berning SE

1 reference

6 July 2017

publication date

1 January 2001

1 reference

6 July 2017

1 reference

6 July 2017

1 reference

6 July 2017

1 reference

6 July 2017

page(s)

9-18

1 reference

The clinical use of fluoroquinolones for the treatment of mycobacterial diseases

6 July 2017

cites work

1 reference

12 December 2020

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

12 December 2020

Tissue penetration of the new quinolones in humans

1 reference

12 December 2020

gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong.

1 reference

12 December 2020

In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis

1 reference

12 December 2020

Treatment of multidrug-resistant tuberculosis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones

1 reference

12 December 2020

Fluoroquinolones: a new treatment for tuberculosis?

1 reference

12 December 2020

A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of fluoroquinolones

1 reference

12 December 2020

Tuberculosis in children

1 reference

12 December 2020

Sparfloxacin worldwide in vitro literature: isolate data available through 1994.

1 reference

12 December 2020

Activity of quinolones against mycobacteria

1 reference

12 December 2020

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

1 reference

12 December 2020

Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

1 reference

12 December 2020

Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages

1 reference

12 December 2020

Combined effect of pyrazinamide and ofloxacin within the human macrophage

1 reference

12 December 2020

Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

1 reference

12 December 2020

Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis

1 reference

12 December 2020

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

1 reference

12 December 2020

Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum

1 reference

12 December 2020

Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

12 December 2020

In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

1 reference

12 December 2020

Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin

1 reference

12 December 2020

Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.

1 reference

12 December 2020

Chemoprophylaxis of Multidrug-Resistant Tuberculous Infection in HIV-Uninfected Individuals Using Ciprofloxacin and Pyrazinamide

1 reference

12 December 2020

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

12 December 2020

Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages

1 reference

12 December 2020

Using therapeutic drug monitoring to dose the antimycobacterial drugs

1 reference

12 December 2020

Emergence of fluoroquinolone-resistant tuberculosis in New York City.

1 reference

12 December 2020

Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

1 reference

12 December 2020

In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis

1 reference

12 December 2020

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis

1 reference

12 December 2020

Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management

1 reference

12 December 2020

Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance

1 reference

12 December 2020

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

1 reference

12 December 2020

Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin

1 reference

12 December 2020

In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis

1 reference

12 December 2020

In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis

1 reference

12 December 2020

Malabsorption of antituberculosis medications by a patient with AIDS

1 reference

12 December 2020

Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis

1 reference

12 December 2020

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

1 reference

12 December 2020

10.2165/00003495-200161010-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

6 July 2017

1002360060

0 references

1 reference